As also mentioned above, treatment with GLP‐1 RAs may result in loss of both adipose tissue and skeletal muscle, potentially exacerbating frailty in patients with HF, a population already prone to muscle wasting and cardiac cachexia.78, 107. The gene discussed is GLP1R; the disease is hydrops fetalis.